Latest news
Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family
MEDSIR & DEBIOPHARM Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1…
Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego
Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors
Strategikon Closes Series A1 Funding Round to Modernize Clinical Trials Business Operations Worldwide
Challenge pour la Qualité de vie du patient 2024, l’appel à projets est ouvert
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer